Physician profile
Thomas Clegg
NPI 1730162231
$7,312.34
in general payments reported to CMS, 2019-2025
38 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what 85% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $183 · 2021: $1,149 · 2022: $1,265 · 2023: $1,583 · 2024: $988 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,974.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $927.38 | 2021-2025 | Inspire |
| Aerin Medical INC. | $853.99 | 2019-2025 | |
| Genzyme Corporation | $692.42 | 2020-2025 | |
| Glaxosmithkline, LLC. | $657.30 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $608.23 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $387.53 | 2021-2025 | Cuvitru, Takhzyro |
| Intersect Ent, INC. | $383.04 | 2019-2021 | |
| Optinose US, INC. | $307.19 | 2019-2024 | |
| Medtronic, INC. | $300.05 | 2023-2024 | Propel, Nuvent, Stealthstation S8 Platform |
| Grifols USA, LLC | $289.81 | 2020-2025 | Xembify |
| Alk-Abello, INC | $209.27 | 2020-2023 | Grastek, Odactra |
| Csl Behring | $149.27 | 2020-2025 | Hizentra |
| Ars Pharmaceuticals Operations, INC. | $146.30 | 2025 | Neffy |
| Hologic Sales and Service, LLC | $144.38 | 2025 | Coolseal Generator |
| Kaleo, INC. | $131.81 | 2021-2023 | Auvi-Q |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arrinex, INC. | $131.44 | 2019 | |
| Amgen INC. | $130.31 | 2022-2025 | Tezspire, Tavneos |
| Cochlear Americas | $126.83 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $105.76 | 2019-2025 | Fasenra |
| Itamar Medical INC | $86.87 | 2023 | Watchpatone |
| Novartis Pharmaceuticals Corporation | $79.10 | 2021-2025 | |
| Stryker Corporation | $75.63 | 2019-2022 | |
| Acclarent, INC | $49.43 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $36.59 | 2025 | Xhance |
| Merck Sharp & Dohme LLC | $35.18 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $27.49 | 2024-2025 | Voquezna |
| Galderma Laboratories, L.P. | $26.45 | 2025 | Nemluvio |
| Ambu INC. | $26.01 | 2021 | |
| Aroa Biosurgery Incorporated | $24.57 | 2024 | |
| Kedrion Biopharma, INC. | $24.26 | 2022 | |
| Incyte Corporation | $23.27 | 2023 | Opzelura |
| Blueprint Medicines Corporation | $23.12 | 2025 | Ayvakit |
| Medtronic USA, INC. | $20.99 | 2019 | |
| Hikma Pharmaceuticals USA | $17.41 | 2023 | Ryaltris |
| Resmed Corp | $15.70 | 2025 | |
| Olympus America INC. | $13.86 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Clegg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.